Development and Validation of a High Performance Liquid Chromatographic Method for Related Substances of Raloxifene Hydrochloride in Bulk and Pharmaceutical Formulations

Authors

  • Ritesh Mishra API Analytical Research & Development Department, Medilux Laboratories Pvt. Ltd. Pithampur, Dist. Dhar. (M.P.), India
  • Satish Matkar API Analytical Research & Development Department, Medilux Laboratories Pvt. Ltd. Pithampur, Dist. Dhar. (M.P.), India
  • Hitesh Malvia API Analytical Research & Development Department, Medilux Laboratories Pvt. Ltd. Pithampur, Dist. Dhar. (M.P.), India
  • M.Asif Khan API Analytical Research & Development Department, Medilux Laboratories Pvt. Ltd. Pithampur, Dist. Dhar. (M.P.), India

DOI:

https://doi.org/10.37591/tdd.v1i1.260

Abstract

The development and validation of reversed phase liquid chromatographic method for the determination of the related substances of Raloxifene Hydrochloride (RLH) in bulk and pharmaceutical formulation is describe. This method is simple isocratic for separation of Raloxifene Hydrochloride and related substances from each other in a thirty minutes run time. To the best of our knowledge, no method described previously in the literature has demonstrated resolution of RLH from this set of related substances. No method for the determination of related substances of Raloxifene hydrochloride is currently described in the Indian pharmacopoeia, United State pharmacopoeia or European pharmacopoeia. The proposed method was validated with respect to accuracy, precision, linearity, and specificity. In addition, the method was determined to be robust with regard to the following parameters: mobile phase apparent pH; mobile phase organic content; detection wavelength and time dependence of sample and standard stability.

 

Keywords: Raloxifene Hydrochloride, related substances, HPLC, pharmaceutical formulation, bulk drug

Downloads

Published

2019-02-21

Issue

Vol. 1 No. 1 (2014)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.